There is a story we hear from patients often enough now that it has started to feel like a pattern.

A person in their forties or fifties, fit by most measures, has been exercising consistently for years. Resistance training three or four times a week. Cardio on the off days. Diet is dialled in, sleep is good, stress is managed. By every behaviour the textbooks would prescribe, this person is doing it right. But the weight will not move, or if it moves it comes back, and a body that used to respond to effort has stopped responding the way it used to.

So they start weight management therapy, expecting the medication to do its work on appetite while everything else they had built stays intact. Within a few months the weight is finally coming off. But something else has changed too, quietly. The training schedule has gaps in it. The reasons to skip a session sound more reasonable than they used to. The internal pull that used to make exercise feel automatic is muted. They are not lazy. They are not depressed. They are doing what they have always done, except now it feels like wading through water.

At Anova we think this experience deserves a name, an explanation, and a place in the clinical conversation that it currently does not have.

What the brain research actually shows

For a long time the assumption was that GLP-1 medications worked almost entirely through the gut. The model is incomplete. GLP-1 receptors are also distributed through parts of the brain that have nothing to do with digestion, including the nucleus accumbens, the ventral tegmental area, and the central amygdala. These are the regions that govern reward, motivation, and the wanting that makes a person work for something.

In October 2025, a research group released preliminary findings showing that semaglutide reduces voluntary wheel running in mice, a task widely used in neuroscience as a proxy for exercise motivation. The reduction was not subtle, and the mechanism mapped onto altered dopamine dynamics in the nucleus accumbens, with the medication attenuating the dopaminergic surge that usually precedes a bout of effort.

A separate group at the University of Virginia, also reporting in 2026, identified a specific pathway running from the hindbrain through the central amygdala to dopamine-producing neurons, and argued that this circuit explains both the appetite suppression and the reduction in motivation to pursue rewarding behaviours generally.

This is animal work, and it does not perfectly predict human experience. But it is consistent with what patients describe, and it lines up with the older receptor mapping studies showing GLP-1 binding sites throughout the mesolimbic reward system. The medication that reduces the wanting of food may also, in some people, reduce the wanting of effort.

What the patient-reported data adds

A 2026 study in Nature Health analysed more than 400,000 Reddit posts from around 67,000 self-identified GLP-1 users between 2019 and 2025, and found that 16.1% of semaglutide users reported fatigue as a side effect. That figure runs higher than the fatigue rates captured in pivotal clinical trial reporting, which is the kind of gap you often see between trial reporting and real-world experience.

Some of this fatigue is straightforwardly mechanical. A person eating 30 to 40% fewer calories has less fuel available, and the body’s response to a sustained energy deficit is to downregulate energy expenditure. Adaptive thermogenesis is the technical name for this. Resting metabolic rate falls. Spontaneous movement falls. Exercise feels harder because, at a cellular level, it actually is harder.

What is harder to disentangle is whether the muted motivation is fatigue presenting as low motivation, or motivation suppression presenting as fatigue, or both at once in proportions that vary between people. Our reading of the current evidence is that it is genuinely both, and that the two reinforce each other.

The hidden calorie arithmetic

This is where the picture becomes clinically important and gets discussed almost nowhere.

A person who was previously doing four moderate-intensity sessions a week, mixing resistance and cardiovascular work, was likely expending roughly 300 to 500 kcal per session, or 1,200 to 2,000 kcal per week from structured exercise alone. Non-exercise activity, the spontaneous movement of an engaged person, adds a meaningful further amount on top.

When GLP-1 motivation suppression cuts that four-session week down to two, the structured exercise deficit drops to 600 to 1,000 kcal per week. When the non-exercise activity quietly falls too, which it tends to, the total weekly energy expenditure can fall by 1,000 to 2,000 kcal per week.

That is a meaningful drag on the medication’s net effect, and it is invisible. The patient sees the scale moving and assumes the program is working. The prescriber sees the weight loss and assumes the dose is right. Neither sees the gap between what the medication should be doing and what it is actually delivering.

This matters because the weight loss is also where muscle preservation happens. Less training plus a caloric deficit is the recipe for losing weight from lean mass rather than from fat. The number on the scale is the same. The body composition outcome is much worse.

An open clinical question worth flagging

The standard escalation protocol for these medications follows a one-way ladder: low starting dose, weekly or four-weekly steps upward, settle at the highest tolerated dose. That model is being quietly questioned in obesity medicine. Maintenance-dose research is increasingly showing that many patients sustain their results on substantially lower doses than they reached during active weight loss, and a 2024 European Congress on Obesity study suggested that lower doses of a GLP-1 medication were as effective as higher doses for some patients.

What is not yet in the literature, but we think is worth raising, is whether the same principle should apply in the active treatment phase for patients who are tolerating the medication well but losing motivation and exercise capacity at the higher dose. Standard practice would not flag this person as a candidate for dose reduction. They are not nauseous. They are losing weight. The protocol says keep going.

But if a previously active patient has dropped from four exercise sessions a week to one, and is losing weight from lean mass as a result, the cumulative twelve to twenty-four month outcome may be better at a lower dose where motivation and movement remain intact. This is a hypothesis, not a recommendation. The framework for thinking about this kind of decision does not yet exist in the published evidence, and it is a discussion for treating clinicians, not for the internet.

Working with the new normal

For patients sitting in this themselves, the practical shift is from relying on motivation to relying on structure.

Motivation, as a system, is unreliable on these medications in a way it might not have been before. So the systems that used to need motivation now need to run on something else:

  • Sessions scheduled like medical appointments, not as decisions to be made each morning
  • The same gym, the same time, the same opening routine, so the friction of starting is as low as possible
  • Smaller minimum doses, set deliberately low, so that on the days when the pull to skip is strong, the session is still small enough to complete

Lower the bar for what counts as a successful session. Maintaining strength is the goal during weight loss, not improving it. Three working sets of a movement done well is more useful than a five-set workout that does not happen. Showing up is the metric that matters.

And pay attention to fatigue patterns over weeks rather than days. Most patients find their energy stabilises somewhere between months three and four. Some find that the motivation does not fully return to where it was. Both outcomes are workable if the routine has been designed for them.

What this should change in the clinical conversation

This is where we think the consultation needs to evolve. Patients starting weight management therapy are typically told to maintain or increase their exercise to preserve muscle mass during weight loss, and that advice is correct. They are not usually told that the medication may make exercise feel different, that early fatigue is common and often substantial, and that the motivation they have always relied on may not be available in the same way for the first few months.

The cost of not having this conversation is real. Patients who have always been disciplined about exercise read the change as personal failure. They push harder, get more depleted, then quit altogether. The exercise habit, which is the single most important thing for muscle preservation during rapid weight loss, becomes a casualty of an entirely predictable physiological response that nobody warned them about.

The conversation we think prescribers should be having looks something like this:

  • Normalise the experience. Exercise motivation can shift on these medications. It is a recognised neurochemical effect, not a character problem.
  • Recalibrate the prescription. The person who lifted four times a week may need to aim for two sessions of slightly lower intensity during dose escalation. That is sensible adaptation, not a step back.
  • Prioritise the right things. Resistance training to preserve muscle mass is non-negotiable. Cardiovascular work matters but the volume can flex. Everything else is optional during adaptation.
  • Watch the calorie arithmetic. If exercise has dropped substantially, the medication is delivering a weight loss outcome that includes a hidden cost in muscle. The plan should account for it.

What we think matters

GLP-1 weight management therapy works, and it works because of effects on appetite and metabolism that are now well documented. But these medications act on the brain as well as the gut, and the brain effects do not stop at appetite. The dopaminergic reward pathways that drive motivation are part of the circuit, and patients deserve to know that exercise may feel different, particularly in the first months.

If you are in this bind, the version of you that exercised on the strength of feeling motivated may not be the version of you that exists for the next few months. That is not a failure. It is a predictable physiological response to a medication that is also doing something you want it to do.

And if your current routine feels impossible to maintain, that is a conversation worth having with your treating clinician. Exercise prescription during weight management therapy should be adapted to the person’s actual energy and motivation, and in some cases the dose or pace of escalation may itself be worth revisiting.

References used in this piece are listed in the sources section. This article does not constitute medical advice. Speak with your treating clinician about any health decisions.